Harvard Bioscience, Inc.
HBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $20 | $25 | $92 |
| - Cash | $7 | $7 | $6 | $4 |
| + Debt | $7 | $43 | $45 | $44 |
| Enterprise Value | – | $56 | $64 | $132 |
| Revenue | $21 | $20 | $22 | $25 |
| % Growth | 0.7% | -6.1% | -11.3% | – |
| Gross Profit | $12 | $10 | $12 | $14 |
| % Margin | 58.4% | 50.7% | 56% | 57.1% |
| EBITDA | $1 | $0 | -$48 | $3 |
| % Margin | 5.6% | 0.8% | -222% | 13% |
| Net Income | -$1 | -$2 | -$50 | $0 |
| % Margin | -6% | -11.2% | -231.2% | 0.1% |
| EPS Diluted | -0.03 | -0.052 | -1.14 | 0 |
| % Growth | 41.7% | 95.5% | -285,100% | – |
| Operating Cash Flow | $1 | $3 | $3 | $2 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$0 |
| Free Cash Flow | $1 | $3 | $2 | $1 |